Henan Cancer Hospital

This trial is testing whether artificial intelligence can create 'digital twin' models of esophageal cancer patients to predict how they will respond to a combination of immunotherapy and chemotherapy. The study will compare the AI's predictions against real outcomes in patients …

This Phase 2 trial tests lisaftoclax, an oral drug that blocks a protein helping cancer cells survive. It enrolls 75 adults with certain slow-growing lymphomas (CLL, WM, or MZL) who either cannot take standard BTK inhibitors due to health issues or have stopped them due to side e…

This trial compares how well patients tolerate dalpiciclib versus abemaciclib or ribociclib when each is combined with standard hormone therapy for high-risk HR+/HER2- early breast cancer. About 456 patients who have completed initial local treatment will be randomly assigned to …

This phase 1 trial tests an experimental drug, sacituzumab tirumotecan (SKB264), given directly into the spinal fluid of people with a specific type of lung cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). The study enrolls adults who…

This phase 2 trial tests whether combining the immunotherapy drug toripalimab with a specific chemotherapy regimen can shrink tumors in people with advanced small cell lung cancer that has progressed after prior treatments. Participants receive toripalimab plus a rotating schedul…

This phase 2 study tests whether combining two oral drugs — lisaftoclax and pirtobrutinib — can shrink or control mantle cell lymphoma in adults whose cancer has stopped responding to or caused intolerance to prior BTK-targeted treatments. Participants take both pills daily until…

This study tests whether giving a combination of chemotherapy directly into the liver (HAIC) plus two drugs (camrelizumab and apatinib) before and after surgery can prevent liver cancer from returning in high-risk patients. About 208 people with resectable liver cancer and high-r…

This phase 2 trial tests a combination of three drugs—retlirafusp alfa, apatinib, and nab-paclitaxel—in 50 adults with advanced stomach or gastroesophageal junction cancer that has progressed after first-line immunotherapy. The goal is to see if the combination can shrink tumors …

This study looks at three different drug combinations for people newly diagnosed with a slow-growing blood cancer called marginal zone lymphoma. The goal is to see which combination works best to shrink tumors and keep the cancer from coming back, while also checking for side eff…

This study looks at how well the drug glofitamab works for people with a type of blood cancer called diffuse large B-cell lymphoma that did not respond to or came back after initial treatment. About 20 adults will take part, and their doctors will decide if they get glofitamab al…

This phase 2 trial tests whether a new drug, trastuzumab-rezetecan, works as well as the established drug T-DXd in shrinking HER2-positive breast tumors before surgery. About 68 women with early or locally advanced breast cancer will receive one of the two drugs for 8 cycles, the…

This study tests a three-part treatment for people with liver cancer that has spread into the main vein of the liver (portal vein tumor thrombus). Participants will receive radiation therapy, followed by two drugs (tislelizumab and anlotinib) to boost the immune system and block …

This study tests whether the drug toripalimab, given after surgery, can help prevent esophageal cancer from returning in patients at high risk of recurrence. About 435 adults who have already had chemotherapy and immunotherapy before surgery will either receive toripalimab or be …

This Phase 2 trial tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. About 216 participants will receive either toripalimab plus one of two chemotherapy regimens. The main goa…

This study tests whether a combination of two anti-nausea drugs (rolapitant and palonosetron) can prevent vomiting and severe nausea in 238 lung cancer patients receiving both chemotherapy and radiation. The goal is to improve comfort during treatment. Participants will be follow…

This study looks back at medical records of 350 people with advanced non-small cell or small cell lung cancer who took anlotinib after their previous treatment stopped working. The goal is to see how well anlotinib works and how safe it is when used in later lines of therapy. The…

This study aims to develop an AI system that helps doctors choose the best treatment for esophageal cancer. Researchers will collect data from 7,000 patients, including medical images and tissue samples, to train a computer model that predicts how well a patient will respond to t…